A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2004 monotherapy in patients with advanced tumors.
Jordan Ellis Cohen, Udit Nindra, Ruth Perets, Ravit Geva et autres
0 citationsJournal of Clinical Oncology
Anne-Laure Goenaga
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
27Publications signalées
152Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Monoclonal and Polyclonal Antibodies ResearchHER2/EGFR in Cancer ResearchProtein purification and stabilityRadiopharmaceutical Chemistry and ApplicationsCancer Immunotherapy and Biomarkers
Publications récentes
MDX-2001–101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors
E Dumbravă, Anna Minchom, Jason T. Henry, Melissa L. Johnson et autres
0 citationsFuture Oncology
843 First-in-human dosing model for MDX2004, a novel trispecific CD3xCD28/4–1BB antibody-fusion protein for advanced malignancies
Bhabuk Koirala, Soumya Rao, Monette Cotreau, Edward Seung et autres
0 citationsRegular and Young Investigator Award Abstracts
1156 MDX2004, a novel immune rejuvenator targeting CD3, CD28, and 4–1BB, augments tumor immunity in preclinical animal models
Edward Seung, Mark Greci, Nicholas Jones, Leon Brown et autres
0 citationsRegular and Young Investigator Award Abstracts
A phase 1/2a, multicenter, first-in-human, open-label clinical trial evaluating MDX2001, a tetraspecific T cell engager-expander in patients with advanced solid tumors.
Ecaterina E. Dumbrava, Kerry Culm, Lukas Makris, Melissa L. Johnson et autres
1 citationJournal of Clinical Oncology
1317 A quantitative systems pharmacology model for first-in-human dosing of MDX2001, a multispecific antibody for the treatment of advanced solid tumors
Marc Presler, Tim Lezon, Marissa Renardy, Monette Cotreau et autres
0 citationsRegular and Young Investigator Award Abstracts
Supplementary Figure Legend from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
Supplementary Table 3 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
Supplementary Figure 1 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Zhou Yu, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
Supplementary Figure 2 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
Supplementary Table 1 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
Supplementary Table 2 from Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Yu Zhou, Anne-Laure Goenaga, Brian D. Harms, Hao Zou et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.